The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer Cells
Abstract
Azurin, a member of the cupredoxin family of copper containing redox proteins, preferentially penetrates human cancer cells and exerts cytostatic and cytotoxic (apoptotic) effects with no apparent activity on normal cells. Amino acids 50 to 77 (p28) of azurin seem responsible for cellular penetration and at least part of the antiproliferative, proapoptotic activity of azurin against a number of solid tumor cell lines. We show by confocal microscopy and fluorescence-activated cell sorting that amino acids 50 to 67 (p18) are a minimal motif (protein transduction domain) responsible for the preferential entry of azurin into human cancer cells. A combination of inhibitors that interfere with discrete steps of the endocytotic process and antibodies for caveolae and Golgi-mediated transport revealed that these amphipathic, α-helical peptides are unique. Unlike the cationic cell-penetrating peptides, α-helical antennapedia-like, or VP22 type peptides, p18 and p28 are not bound by cell membrane glycosaminoglycans and preferentially penetrate cancer cells via endocytotic, caveosome-directed, and caveosome-independent pathways. Once internalized, p28, but not p18, inhibits cancer cell proliferation initially through a cytostatic mechanism. These observations suggest the azurin fragments, p18 and p28, account for the preferential entry of azurin into human cancer cells and a significant amount of the antiproliferative activity of azurin on human cancer cells, respectively. [Cancer Res 2009;69(2):537–46]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of Cytokine Receptors by Golgi N-Glycan Processing and Endocytosis
Partridge, E. A., Le Roy, C., Di Guglielmo, G. M., Pawling, J., Cheung, P., Granovsky, M., Nabi, I. R., Wrana, J. L., & Dennis, J. W. (2004) · Science · doi:10.1126/science.1102109 · Cited by 735
Yamada, T., Hiraoka, Y., Ikehata, M., Kimbara, K., Avner, B. S., Das Gupta, T. K., & Chakrabarty, A. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400899101 · Cited by 98
Self-citation
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery
Wang, F., Wang, Y., Zhang, X., Zhang, W., Guo, S., & Jin, F. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.11.020 · Cited by 377
Liposome delivery systems for the treatment of Alzheimer’s disease
Ross, C., Taylor, M., Fullwood, N., & Allsop, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s183117 · Cited by 198
Zhang, Y., Zhang, Y., Xia, L., Zhang, X., Ding, X., Yan, F., & Wu, F. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.01390-12 · Cited by 138
Advances and prospects of cell-penetrating peptides in tumor immunotherapy
Yang, D., Liu, B., & Sha, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-86130-8 · Cited by 31
Metadata
- Authors
- Taylor, B. N., Mehta, R. R., Yamada, T., Lekmine, F., Christov, K., Chakrabarty, A. M., Green, A., Bratescu, L., Shilkaitis, A., Beattie, C. W., & Das Gupta, T. K.
- Venue
- Cancer Research
- Published
- 2009-01-15
- Volume
- 69
- Issue
- 2
- Pages
- 537-546
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2127582578
- Cited by
- 184
- References
- 2
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-2932
- The paper
- Taylor, B. N., Mehta, R. R., Yamada, T., Lekmine, F., Christov, K., Chakrabarty, A. M., Green, A., Bratescu, L., Shilkaitis, A., Beattie, C. W., & Das Gupta, T. K. (2009). Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-2932
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.